Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T12:50:56.950Z.
Calculation as of: 2026-10-06T12:50:56.950Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c0c25a561797b8251bbc96a681ec43d66f95a8f813bb62f19698de697ac6593e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Market Cap
$49.40M
Free Cash Flow Yield
39.84%
TTM Avg
42.72%
3Y Avg
26.54%
5Y Avg
31.80%
Market Cap
$51.12M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$46.79M
Free Cash Flow Yield
N/A
TTM Avg
8.38%
3Y Avg
7.29%
5Y Avg
5.95%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celularity Inc. (CELU) | $49.50M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $49.40M | 39.84% | 42.72% | 26.54% | 31.80% |
| Clene Inc. (CLNN)vs › | $49.96M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $50.25M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $50.51M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.58M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $46.79M | N/A | 8.38% | 7.29% | 5.95% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.95M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
